- Home
- OLMA
as of 12-26-2025 3:59pm EST
$26.20
$1.39
-5.04%
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 2.6B | IPO Year: | 2020 |
| Target Price: | $40.50 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.86 - $36.26 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered OLMA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 69.74%
69.74%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Olema Pharmaceuticals Inc. (OLMA)
Zojwalla Naseem
Sell
Chief Medical Officer
OLMA Dec 23, 2025
Avg Cost/Share
$27.66
Shares
99,509
Total Value
$2,752,418.94
Owned After
4,488
SEC Form 4
Zojwalla Naseem
Sell
Chief Medical Officer
OLMA Dec 22, 2025
Avg Cost/Share
$28.04
Shares
100,000
Total Value
$2,804,000.00
Owned After
4,488
SEC Form 4
CLARK IAN T
Sell
Director
OLMA Dec 19, 2025
Avg Cost/Share
$29.67
Shares
264,800
Total Value
$7,873,109.28
Owned After
41,840
Myles David C.
Sell
CH. DISCOV. & NON-CLIN DEV OFF
OLMA Dec 19, 2025
Avg Cost/Share
$29.96
Shares
51,000
Total Value
$1,553,543.54
Owned After
551,881
Zojwalla Naseem
Sell
Chief Medical Officer
OLMA Dec 19, 2025
Avg Cost/Share
$28.48
Shares
70,000
Total Value
$1,973,728.90
Owned After
4,488
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Zojwalla Naseem | OLMA | Chief Medical Officer | Dec 23, 2025 | Sell | $27.66 | 99,509 | $2,752,418.94 | 4,488 | |
| Zojwalla Naseem | OLMA | Chief Medical Officer | Dec 22, 2025 | Sell | $28.04 | 100,000 | $2,804,000.00 | 4,488 | |
| CLARK IAN T | OLMA | Director | Dec 19, 2025 | Sell | $29.67 | 264,800 | $7,873,109.28 | 41,840 | |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Dec 19, 2025 | Sell | $29.96 | 51,000 | $1,553,543.54 | 551,881 | |
| Zojwalla Naseem | OLMA | Chief Medical Officer | Dec 19, 2025 | Sell | $28.48 | 70,000 | $1,973,728.90 | 4,488 |
Latest Olema Pharmaceuticals Inc. News
OLMA Breaking Stock News: Dive into OLMA Ticker-Specific Updates for Smart Investing
MT Newswires
Olema Pharmaceuticals Insider Sold Shares Worth $1,553,544, According to a Recent SEC Filing
⚠️
AI Sentiment
Highly Negative
1/10
MT Newswires
Olema Pharmaceuticals Insider Sold Shares Worth $7,873,109, According to a Recent SEC Filing
📉
AI Sentiment
Negative
2/10
MT Newswires
Olema Pharmaceuticals Insider Sold Shares Worth $7,530,148, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
4/10
Compare OLMA vs Leading Stocks
See how OLMA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "OLMA Olema Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.